Oil prices rebound sharply on smaller-than-feared OPEC+ output hike
Investing.com - Rothschild Redburn downgraded Medpace (NASDAQ:MEDP) from Buy to Neutral on Wednesday, while raising its price target to $474.00 from $342.00. According to InvestingPro data, the stock currently trades near its 52-week high of $501.30, with a P/E ratio of 34x and an EV/EBITDA multiple of 26.5x.
The research firm cited valuation concerns following the stock’s recent performance, noting that Medpace shares now trade at 33x FY25 and 29x FY26 adjusted earnings per share, broadly in line with its ten-year average forward P/E multiple of 30x. InvestingPro analysis indicates the stock is currently overvalued, with additional valuation insights available in the Pro Research Report.
Medpace stock reacted positively to earnings revisions following its second-quarter 2025 results, driven by some of the company’s customers receiving funding, though Rothschild Redburn cautioned that the sustainability of such funding remains uncertain. InvestingPro Tips highlight that three analysts have revised their earnings upwards for the upcoming period, while management has been actively buying back shares.
The firm acknowledged that Medpace is positioned to generate the fastest revenue growth among contract research organization stocks over the next 12 months, with its share price and multiple proving most resilient during the sector’s downturn over the past year.
Rothschild Redburn forecasts a 2025-28 EPS compound annual growth rate of 11% for Medpace on a revenue CAGR of 9%, with current forecasts not assuming future share buybacks.
In other recent news, Medpace Holdings Inc . reported impressive financial results for the second quarter of 2025, surpassing expectations with an earnings per share (EPS) of $3.10, compared to the forecasted $2.98. The company also exceeded revenue predictions, bringing in $603.3 million against an anticipated $538.81 million. Despite these strong earnings, UBS downgraded Medpace’s stock rating from Neutral to Sell, although it slightly increased its price target to $305.00. Similarly, TD Cowen downgraded the stock from Hold to Sell, while raising its price target to $366.00. UBS maintained a Neutral rating with a $300.00 price target, noting a mixed outlook despite the company’s robust Q2 performance. These developments highlight a cautious approach by analysts, who emphasize ambitious targets and short covering as factors influencing recent stock movements. Medpace’s improved Q2 bookings and raised guidance present a challenging scenario for analysts maintaining a conservative outlook.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.